US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.61

+0.08000.64%

Volume:199.74K

Turnover:2.52M

Market Cap:696.76M

PE:10.69

High:12.64

Open:12.54

Low:12.54

Close:12.53

52wk High:13.59

52wk Low:12.50

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.58

T/O Rate:0.36%

Dividend:1.42

Dividend Rate:11.22%

EPS(TTM):1.18

ROE:--

ROA:--

PB:0.87

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Press Release: First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Heron Therapeutics Announces Second Quarter 2026 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/RA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.61,"timestamp":1787678113590,"preClose":12.53,"halted":0,"volume":199738,"delay":0,"changeRate":0.006384676775738235,"floatShares":55245934,"shares":55254696,"eps":1.18,"marketStatus":"Trading","change":0.08,"latestTime":"08-25 13:16:32 EDT","open":12.54,"high":12.64,"low":12.54,"amount":2516813.849088,"amplitude":0.007981,"askPrice":12.61,"askSize":100,"bidPrice":12.5,"bidSize":2700,"shortable":3,"etf":0,"ttmEps":1.18,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.53,"dividendRate":0.112244,"preHourTrading":{"tag":"盘前","latestPrice":12.54,"preClose":12.53,"latestTime":"08:53 EDT","volume":32,"amount":401.270112,"timestamp":1787662393874,"change":0.01,"changeRate":0.000798,"amplitude":0.000806},"postHourTrading":{"tag":"盘后","latestPrice":12.53,"preClose":12.53,"latestTime":"19:30 EDT","volume":16,"amount":200.5204,"timestamp":1787614206669,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.582395},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.582395,"shares":55254696,"dividePrice":1.4154,"high":12.64,"amplitude":0.007981,"preClose":12.53,"low":12.54,"week52Low":12.5,"pbRate":"0.87","week52High":13.59,"institutionHeld":0,"latestPrice":12.61,"committee":0.928571,"eps":1.18,"divideRate":0.112244,"volume":199738,"delay":0,"ttmEps":1.18,"open":12.54,"prevYearClose":12.96,"prevWeekClose":12.55,"prevMonthClose":12.81,"prevQuarterClose":12.88,"fiveDayClose":12.63,"twentyDayClose":12.79,"sixtyDayClose":12.78},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-09-10","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-10","defaultRemindTime":1789047000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-24","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1789012800000,"payDate":"2026-09-24"},{"date":"2026-08-06","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-20","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-20"},{"date":"2026-07-09","symbol":"RA","amount":0.118,"announcedDate":"2026-06-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-09","defaultRemindTime":1783603800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-23","payableDate":"2026-07-09","currency":"USD","dateTimestamp":1783569600000,"payDate":"2026-07-23"},{"date":"2026-06-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"date":"2026-05-07","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-07","defaultRemindTime":1778160600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-21","payableDate":"2026-05-07","currency":"USD","dateTimestamp":1778126400000,"payDate":"2026-05-21"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660178421","title":"Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2660178421","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660178421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:26","pubTimestamp":1787142360,"startTime":"0","endTime":"0","summary":"Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected byyear-end RA is a $24 billion m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/19/3347616/0/en/chemomab-therapeutics-announces-second-quarter-2026-financial-results-and-provides-corporate-update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTRS","LENZ","BK4539","RA","BK4139","BK4007","PSC","IBD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659009089","title":"Press Release: First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659009089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659009089?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:15","pubTimestamp":1786565700,"startTime":"0","endTime":"0","summary":"-- Completed enrollment for Cohort 1  of Phase 1b ANB033. trial in celiac disease ; top-line Cohort 1 data reaffirmed for Q4. -- Cohort 2  enhanced to enroll up to 40 patients including. those with a broad range of histologic  and symptom. severity to further inform future development; top-line Cohort 2 data. -- U.S. FDA granted Fast Track designation for ANB033 for the treatment of. -- Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis. -- Reiterating cash-runway into Q2 2028, including the expansion of ANB033. -- U.S. FDA granted Fast Track designation to ANB033 for the. treatment of people with CeD on a gluten-free diet. -- 70-patient trial assessing one dose level of subcutaneously. -- Cohort 1  is a gluten-challenge study to assess the. -- Cohort 2  assesses the possibility of mucosal healing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLE","BK4077","TRAX","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658915593","title":"Press Release: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915593?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:30","pubTimestamp":1786455000,"startTime":"0","endTime":"0","summary":"placebo-controlled Phase 3 registrational trial with an open-label. extension assessing the efficacy and safety of telitacicept in gMG. -- Topline data anticipated in 1H 2027Primary Sjgren's Disease-- UPSTREAM SjD. efficacy and safety of telitacicept in SjDCorporate Updates-- Appointed David Zaccardelli, Pharm.D., former Chief Executive Officer and. President of Verona Pharma, to its Board of Directors. approved telitacicept for the treatment of adult patients with SjD and. -- Results from the Phase 3 TELIGAN trial evaluating telitacicept in IgAN in. China were published in The New England Journal of MedicineSecond Quarter 2026 Financial Results-- Cash Position: Cash, cash equivalents and marketable securities were. $466.1 million as of June 30, 2026, which together with the $48.4 million. net proceeds from at-the-market sales during July 2026, are projected to. -- Research & Development (R&D) Expenses: R&D expenses for the second. quarter of 2026 were $25.9 million, compared to $261.5","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","VOR","BK4139","BK4077","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658693652","title":"Heron Therapeutics Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658693652","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658693652?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:00","pubTimestamp":1786363200,"startTime":"0","endTime":"0","summary":"– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF net revenue grew 35% and APONVIE net revenue grew 74% year-over-year – Amended credit facility with Hercules Capi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341780/0/en/heron-therapeutics-announces-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","CINV","HRTX","BK4563","BK4139","BK4161","IE0031619046.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","MEC","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":14,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RA\",params:#limit:6,delay:false,,,undefined,":[]}}